Updated on 29 October 2026
3D cell models, multi-omics, RNA biology and structure for PM consortia
Commercialization coordinator at IMol PAS at IMol Polish Academy od Sciences
Warsaw, Poland
About
IMol PAS (https://imol.institute/) is a multidisciplinary research institute located in Warsaw, established in 2021. With scientific excellence as one of our core pillars, we conduct cutting-edge research combining molecular and cell biology, cancer biology, proteomics, chemical biology, and medicinal chemistry.
We are eager to join multinational, multidisciplinary consortia dedicated to addressing unmet medical needs and improving access to effective preventive and therapeutic interventions.
Our expertise includes:
-
functional and mechanistic target validation;
-
in vitro models for drug development, including tumor-on-chip, brain-on-chip, organoids, and iPSC-based models;
-
compound screening in zebrafish;
-
generation and integration of multi-omics data, particularly proteomics and chemoproteomics;
-
cancer signaling and tumor–microenvironment interactions;
-
RNA biology, RNA processing, and regulation of gene expression;
-
mitochondrial biology and mitochondrial protein homeostasis;
-
proteostasis and metabolic quality control;
-
membrane biology and cellular mechanisms;
-
molecular pharmacology and chemical biology.
Similar opportunities
Project cooperation
From Genomic Hits to Therapeutic Targets: IMol as partner in Health and Biotech projects
- Partner seeks Consortium/Coordinator
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 6: HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Destination 4: HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- Destination 2: HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Magdalena Grodecka
Commercialization coordinator at IMol PAS at IMol Polish Academy od Sciences
Warsaw, Poland
Project cooperation
- Destination 6: HORIZON-HLTH-2027-02-IND-02-two-stage: Portable and versatile Point-of-care diagnostics
- Destination 3: HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
- Destination 5: HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- Destination 5: HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Ayse Caner
Professor of Basic Oncology and Parasitology | Ege University, Türkiye at Ege University, Faculty of Medicine
izmir, Türkiye
Project cooperation
Ariadna Bargiela
Group leader at FUNDACIÓN INCLIVA
Valencia, Spain